

BLG completes third only corporate IPO on the TSX in 2016 for Cannimed Therapeutics Inc.

Date closed: 12/29/2016

Value: C\$60 million

On December 29, 2016, CanniMed Therapeutics Inc., (CMED) a leading plant biopharmaceutical company specializing in the production of pharmaceutical-grade cannabis, successfully completed an initial public offering of its common shares (the Offering) on December 29, 2016. In connection with the Offering, CMED issued 5,000,000 common shares at a price of C\$12.00 per common share, resulting in aggregate gross proceeds to CMED of C\$60,000,000. CMED's common shares began trading on the Toronto Stock Exchange under the symbol "CMED".

The Offering was made through a syndicate of underwriters led by AltaCorp Capital Inc. and included Canaccord Genuity Corp., Clarus Securities Inc., Mackie Research Capital Corporation and Haywood Securities Inc.

BLG represented CMED with a team led by [Philippe Tardif](#) that included Andrew Powers, [Linda Tu](#), [Colin Cameron-Vendrig](#), [Joseph Di Ponio](#), [Danny Lang](#), [David Wood](#), [Francine Ferrer](#) and [Chris Savo](#).

For more information, please contact:

Tamara Costa

National Director, Marketing and Communications

Borden Ladner Gervais LLP

TCosta@blg.com

416.350.2642



BLG | Canada's Law Firm

As the largest, truly full-service Canadian law firm, Borden Ladner Gervais LLP (BLG) delivers practical legal advice for domestic and international clients across more practices and industries than any Canadian firm. With over 725 lawyers, intellectual property agents and other professionals, BLG serves the legal needs of businesses and institutions across Canada and beyond – from M&A and capital markets, to disputes, financing, and trademark & patent registration.

[blg.com](https://www.blg.com)

© 2025 Borden Ladner Gervais LLP. Borden Ladner Gervais LLP is an Ontario Limited Liability Partnership.